...

BillionToOne

United States

About BillionToOne

BillionToOne is a pioneering molecular diagnostics company that specializes in genetic screening, primarily through its innovative prenatal testing and oncology solutions. Founded in 2016, the company has developed the proprietary Quantitative Counting Template (QCT) technology, which powers its flagship product, the UNITY Screen. This non-invasive prenatal test allows for comprehensive genetic screening from a single maternal blood draw, making it a preferred choice for OB/GYN practices. With a growing market share of 15% in the U.S. prenatal testing sector, BillionToOne is on track to achieve $153 million in revenue in 2024, more than doubling from the previous year.

In addition to its prenatal offerings, BillionToOne has made significant strides in the oncology market with its Northstar platform, which detects cancer mutations in blood samples. This expansion taps into a lucrative $50 billion market, with the company rapidly scaling to thousands of tests per quarter. The Northstar Select and Response tests provide oncologists with critical insights for therapy selection and treatment monitoring, showcasing the platform's superior detection capabilities.

What sets BillionToOne apart is its commitment to operational efficiency and high gross margins, exceeding 60%. As the company continues to innovate and expand its QCT technology into new areas, it aims to redefine the landscape of molecular diagnostics, with a vision for sustainable growth and enhanced patient outcomes.

News

May 16th, 2025

BillionToOne Expands UNITY Fetal Risk Screen to Assess 14 Genetic Conditions

BillionToOne's expansion of the UNITY Fetal Risk Screen enhances prenatal genetic testing capabilities, potentially reshaping healthcare decision-making and driving demand for personalized medicine in reproductive health.
Related Articles: PR Newswire Femtech Insider Contemporary Pediatrics
February 27th, 2025

BillionToOne Achieves 100% Accuracy in Non-Invasive Prenatal Test for Fetal RhD Status

BillionToOne's breakthrough in non-invasive prenatal testing not only enhances maternal-fetal health but also positions the company as a leader in precision medicine, potentially reshaping prenatal care and influencing market dynamics in genetic testing.
Related Articles: PR Newswire Medical Device Network Yahoo Finance
December 20th, 2024

BillionToOne's UNITY Test Enhances Maternal Care Access in Remote Areas

BillionToOne's UNITY Test significantly improves maternal healthcare accessibility in remote areas, potentially reducing health disparities and fostering better health outcomes for underserved populations.
Related Articles: Femtech Insider WV News PR Newswire
September 4th, 2024

BillionToOne Breaks Ground on New Facility in Austin, Creating 1,000 Jobs

BillionToOne's new facility in Austin not only boosts local employment but also positions the company to enhance its production capabilities, potentially accelerating advancements in precision medicine and diagnostics.
Related Articles: LabPulse.com Urbanize Austin Community Impact KVUE Business Facilities Magazine KVUE LabPulse.com Austin Monitor PR Newswire
July 24th, 2024

BillionToOne Secures $130 Million in Series D Funding to Enhance Prenatal and Oncology Diagnostics

BillionToOne's $130 million funding bolsters its capacity to innovate in prenatal and oncology diagnostics, potentially reshaping healthcare delivery and improving patient outcomes through advanced, accessible testing solutions.
Related Articles: Forbes The Healthcare Technology Report.
June 21st, 2024

BillionToOne Secures $130 Million in Series D Funding, Achieves Unicorn Status

BillionToOne's $130 million funding round not only solidifies its unicorn status but also positions it to accelerate innovation in precision medicine, potentially reshaping healthcare delivery and diagnostics on a global scale.
Related Articles: Crunchbase News Forbes FinSMEs PR Newswire Axios
April 17th, 2024

BillionToOne's UNITY Test Offers Solution Amidst RhoGAM Shortage

BillionToOne's UNITY Test addresses the critical RhoGAM shortage, potentially reshaping prenatal care by providing a reliable alternative that enhances patient outcomes and stabilizes supply chains in the healthcare sector.
Related Articles: BioWorld MedTech PR Newswire
April 9th, 2024

BillionToOne Partners with Culmination Bio to Advance Oncology Diagnostics

BillionToOne's partnership with Culmination Bio enhances its capabilities in oncology diagnostics, positioning the company to capitalize on the growing demand for precision medicine and potentially reshaping competitive dynamics in the healthcare sector.
Related Articles: PharmaTimes Inside Precision Medicine Healthcare Finance News
March 21st, 2024

BillionToOne Launches BabyPeek, a Fun Prenatal Test for Non-Medical Baby Traits

BillionToOne's BabyPeek not only taps into the growing consumer interest in personalized experiences but also raises ethical questions about genetic selection, potentially reshaping prenatal care and parental expectations in the long term.
Related Articles: Medical Device Network HIT Consultant
December 12th, 2023

BillionToOne Partners with Johnson & Johnson for Phase 3 HDFN Clinical Trial

BillionToOne's collaboration with Johnson & Johnson for a Phase 3 clinical trial positions it to potentially revolutionize treatment for hemolytic disease of the fetus and newborn, enhancing its market presence and attracting further investment in innovative healthcare solutions.
Related Articles: Clinical Trials Arena PR Newswire
December 6th, 2022

BillionToOne's UNITY Screen Achieves High Sensitivity in Non-Invasive Prenatal Testing

BillionToOne's UNITY Screen enhances non-invasive prenatal testing accuracy, potentially transforming prenatal care and influencing healthcare cost structures by reducing the need for invasive procedures and associated risks.
Related Articles: SMA News Today PR Newswire
March 30th, 2022

BillionToOne Secures $125 Million in Series C Funding to Expand Molecular Diagnostics

BillionToOne's $125 million funding bolsters its position in the molecular diagnostics market, potentially accelerating innovation and competition in personalized medicine, which could reshape healthcare delivery and patient outcomes.
Related Articles: PR Newswire HIT Consultant
June 14th, 2021

BillionToOne Secures $55 Million in Series B Funding to Expand Noninvasive Prenatal Screening Services

BillionToOne's $55 million funding bolsters its position in the rapidly growing noninvasive prenatal screening market, potentially reshaping prenatal care and influencing healthcare investment trends towards innovative diagnostic solutions.
Related Articles: FinSMEs Newswire Press Release Distribution
November 3rd, 2019

BillionToOne Launches Non-Invasive Prenatal Screening Test in Europe

BillionToOne's launch of a non-invasive prenatal screening test in Europe not only enhances maternal healthcare options but also positions the company to capture a significant share of the growing European genetic testing market.
Related Articles: SMA News Today BioSpace
June 27th, 2019

BillionToOne Launches UNITY, a Revolutionary Prenatal Screening Test

BillionToOne's launch of UNITY positions it at the forefront of prenatal diagnostics, potentially reshaping healthcare practices and influencing market dynamics by enhancing early disease detection and personalized medicine.
Related Articles: BioSpace PR Newswire

Research Reports

BillionToOne at $153M/yr

View Document

BillionToOne revenue, growth, and valuation

View Document

BillionToOne One-Pager

View Document

Neuralink One-Pager

View Document

The $210M/year GitHub of biotech

View Document

Benchling revenue, growth, and valuation

View Document

Benchling One-Pager

View Document

Apeel One-Pager

View Document

Frequently Asked Questions

How would the investment be structured?

When investment opportunities become available for BillionToOne, they would typically be structured through US-based, bankruptcy-remote Delaware SPVs. As an investor, you would become a limited partner in a fund that indirectly holds shares of the company. This page is for expressing interest in future opportunities, not for making actual investments.

Why can't I invest in BillionToOne directly?

Direct investment into high-demand private companies like BillionToOne often requires $50M+ in capital. Our SPV structure gives you access at lower minimums by pooling capital and investing through intermediaries that already hold equity.

What is the minimum investment amount?

The minimum investment typically starts from $10,000, though it may vary depending on the deal size and available allocations.

When will I receive units for my investment?

Once the SPV is fully funded and the shares are secured, units will be allocated to your account and you'll be notified. This typically takes 2–3 weeks post close date.

What are the exit options or liquidity paths?

Liquidity is not guaranteed. However, exits may occur through the following avenues:
(a) resale through our partner's Alternative Trading System (ATS) after a holding period,
(b) secondary market transactions,
(c) a future IPO of BillionToOne or its subsidiaries, or
(d) an acquisition of the company.

What are the risks of investing in BillionToOne?

Key risks include equity risk (share value decline) and liquidity risk (limited tradability of private shares). As with any private market investment, capital loss is possible.

What are the tax implications?

Taxation is treated the same as investing in US-listed stocks. Long-term capital gains (after 24 months) are taxed at 12.5%. Short-term gains are taxed as per your income tax slab.

Under which regulatory framework does this investment fall?

All investments are made through SEC-compliant SPVs under Regulation S. The structure is similar to those used by leading US platforms like EquityZen and Forge.

Need More Information?

Have additional questions about this investment opportunity? Our team is here to help.

Request Callback

Quick Actions

Express Interest Request Callback

Funding Rounds

No funding rounds data available

Scroll to Top